...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer Cell >Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.
【24h】

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

机译：雄激素消融减轻了对前列腺/前列腺癌限制性抗原的耐受性。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

To understand the T cell response to prostate cancer, we created transgenic mice that express a model antigen in a prostate-restricted pattern and crossed these animals to TRAMP mice that develop spontaneous prostate cancer. Adoptive transfer of prostate-specific CD4 T cells shows that, in the absence of prostate cancer, the prostate gland is mostly ignored. Tumorigenesis allows T cell recognition of the prostate gland--but this recognition is tolerogenic, resulting in abortive proliferation and ultimately in hyporesponsiveness at the systemic level. Androgen ablation (the most common treatment for metastatic prostate cancer) was able to mitigate this tolerance--allowing prostate-specific T cells to expand and develop effector function after vaccination. These results suggest that immunotherapy for prostate cancer may be most efficacious when administered after androgen ablation.
机译：为了了解T细胞对前列腺癌的反应，我们创建了以前列腺限制模式表达模型抗原的转基因小鼠，并将这些动物与发展自发性前列腺癌的TRAMP小鼠杂交。前列腺特异性CD4 T细胞的过继转移表明，在没有前列腺癌的情况下，前列腺通常被忽略。肿瘤发生允许T细胞识别前列腺-但这种识别具有耐受性，导致流产性增殖并最终导致全身性反应低下。雄激素消融（转移性前列腺癌最常见的治疗方法）能够减轻这种耐受性，使前列腺特异性T细胞在接种疫苗后得以扩展和发挥效应子功能。这些结果表明，在雄激素消融后给予前列腺癌免疫治疗可能是最有效的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号